ProPhase Labs, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-06-30 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2026-03-31 was $769.00K.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-12-31 was $0.00.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-09-30 was $2.40M.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $3.61M.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $2.40M, a 300.00% increase from fiscal 2022.
- ProPhase Labs, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $600.00K.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | |
| 2026-03-31 | $769.00K 10-Q/A · filed 2026-07-09 | |
| 2025-12-31 | $3.61M 10-K · filed 2026-06-01 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $2.40M 10-K · filed 2025-04-01 |
| 2023-09-30 | $2.40M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $600.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | |
| 2022-03-31 | $600.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |